Agios Pharmaceuticals - AGIO Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $33.50
Forecasted Upside: 5.78%
Number of Analysts: 4
Breakdown:
0 Sell Ratings
2 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$31.67 As of 04/24/2024 01:00 AM ET

▼ -0.14 (-0.44%)

1 month | 3 months | 12 months

Get New Agios Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AGIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGIO

^$33.50

▲ +5.78% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Agios Pharmaceuticals in the last 3 months. The average price target is $33.50, with a high forecast of $42.00 and a low forecast of $28.00. The average price target represents a 5.78% upside from the last price of $31.67.

Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in Agios Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/1/2022

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/30/2023

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/30/2023

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/29/2023

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/27/2023

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/25/2024

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/25/2024

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/24/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/9/2024	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
2/23/2024	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$31.00 ➝ $30.00	Low
2/16/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$43.00 ➝ $42.00	Low
2/8/2024	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
11/3/2023	The Goldman Sachs Group	Lower Target	Neutral ➝ Neutral	$32.00 ➝ $28.00	Low
8/7/2023	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$33.00 ➝ $32.00	Low
5/5/2023	SVB Securities	Lower Target		$37.00 ➝ $34.00	Low
2/3/2023	Piper Sandler	Initiated Coverage	Overweight	$41.00	Low
2/3/2023	Piper Sandler Companies	Initiated Coverage	Overweight	$41.00	Low
11/17/2022	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$17.00 ➝ $32.00	Low
8/5/2022	SVB Leerink	Boost Target	Outperform	$33.00 ➝ $37.00	Low
7/27/2022	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$33.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Sell	$20.00 ➝ $16.00	High
5/17/2022	SVB Leerink	Boost Target	Market Perform	$33.00	Medium
3/7/2022	The Goldman Sachs Group	Lower Target	Sell	$37.00 ➝ $23.00	Medium
3/3/2022	HC Wainwright	Lower Target	Buy	$98.00 ➝ $96.00	Low
2/25/2022	Royal Bank of Canada	Boost Target	Outperform	$61.00 ➝ $67.00	High
2/24/2022	HC Wainwright	Lower Target	Buy	$98.00 ➝ $96.00	High
2/22/2022	SVB Leerink	Lower Target	Market Perform	$32.00 ➝ $30.00	Low
2/18/2022	HC Wainwright	Boost Target	Buy	$95.00 ➝ $98.00	High
2/16/2022	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$52.00 ➝ $44.00	Low
12/3/2021	Bank of America	Initiated Coverage	Buy	$54.00	Medium
11/18/2021	SVB Leerink	Lower Target	Market Perform	$50.00 ➝ $42.00	High
11/4/2021	HC Wainwright	Boost Target	Buy	$93.00 ➝ $95.00	High
7/30/2021	SVB Leerink	Initiated Coverage	Hold	$50.00	Low
7/30/2021	HC Wainwright	Boost Target	Buy	$88.00 ➝ $93.00	Medium
7/30/2021	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$58.00 ➝ $39.00	Low
6/30/2021	Raymond James	Initiated Coverage	Market Perform		Low
6/13/2021	Oppenheimer	Reiterated Rating	Hold		Low
6/10/2021	HC Wainwright	Initiated Coverage	Buy	$88.00	Low
4/30/2021	The Goldman Sachs Group	Initiated Coverage	Neutral		Medium
4/30/2021	Barclays	Boost Target	Positive ➝ Overweight	$65.00 ➝ $70.00	Low
3/8/2021	JPMorgan Chase & Co.	Reiterated Rating	Overweight ➝ Neutral	$54.00	Medium
3/4/2021	SVB Leerink	Reiterated Rating	Outperform ➝ Market Perform	$55.00 ➝ $50.00	High
3/1/2021	SVB Leerink	Upgrade	Market Perform ➝ Outperform		High
3/1/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$64.00 ➝ $54.00	Low
2/26/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$55.00 ➝ $50.00	High
1/27/2021	SVB Leerink	Boost Target	Outperform	$51.00 ➝ $55.00	High
1/27/2021	Barclays	Boost Target	Positive ➝ Overweight	$58.00 ➝ $65.00	High
1/14/2021	Barclays	Boost Target		$50.00 ➝ $58.00	Medium
12/22/2020	SVB Leerink	Lower Target		$61.00 ➝ $51.00	High
12/22/2020	Royal Bank of Canada	Lower Target		$59.00 ➝ $66.00	Medium
12/21/2020	Piper Sandler	Boost Target		$73.00 ➝ $80.00	Low
12/9/2020	BMO Capital Markets	Lower Target		$57.00 ➝ $50.00	High
12/9/2020	SVB Leerink	Lower Target	Outperform	$67.00 ➝ $61.00	High
11/20/2020	Barclays	Boost Target	Overweight	$46.00 ➝ $50.00	High
11/19/2020	Cantor Fitzgerald	Boost Target	Overweight	$68.00 ➝ $79.00	High
10/22/2020	Barclays	Upgrade	Equal Weight ➝ Overweight	$46.00	High
10/19/2020	Needham & Company LLC	Lower Target	Buy	$71.00 ➝ $69.00	Low
10/19/2020	SVB Leerink	Lower Target	Positive ➝ Outperform	$72.00 ➝ $67.00	Medium
10/19/2020	Piper Sandler	Lower Target	Overweight	$80.00 ➝ $73.00	Medium
7/31/2020	Cantor Fitzgerald	Boost Target	Overweight	$70.00 ➝ $72.00	High
7/30/2020	Needham & Company LLC	Initiated Coverage	Buy	$71.00	High
6/15/2020	SVB Leerink	Boost Target	Outperform	$70.00 ➝ $72.00	Medium
6/15/2020	Guggenheim	Boost Target	Buy	$60.00 ➝ $66.00	Medium
6/15/2020	Citigroup	Boost Target	Buy	$64.00 ➝ $75.00	Medium
6/15/2020	Oppenheimer	Reiterated Rating	Hold		Medium
6/12/2020	Piper Sandler	Boost Target	Overweight	$70.00 ➝ $80.00	High
5/4/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$72.00 ➝ $82.00	High
4/30/2020	Oppenheimer	Reiterated Rating	Hold		High
4/30/2020	Needham & Company LLC	Reiterated Rating	Buy	$71.00	Low
3/4/2020	Barclays	Initiated Coverage	Equal Weight	$50.00	High
3/4/2020	Cowen	Reiterated Rating	Buy		High
2/17/2020	Needham & Company LLC	Reiterated Rating	Buy	$71.00	High
2/14/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$64.00 ➝ $70.00	High
2/13/2020	Cowen	Reiterated Rating	Buy		High
2/13/2020	Oppenheimer	Reiterated Rating	Hold		High
1/31/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
1/21/2020	Oppenheimer	Reiterated Rating	Hold		Low
1/14/2020	Cowen	Reiterated Rating	Buy		High
12/10/2019	Cowen	Reiterated Rating	Buy		Low
12/9/2019	BMO Capital Markets	Boost Target	Outperform	$45.00 ➝ $49.00	High
12/4/2019	JPMorgan Chase & Co.	Lower Target	Overweight	$80.00 ➝ $68.00	High
11/26/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$64.00	Medium
11/5/2019	Citigroup	Lower Target	Buy	$80.00 ➝ $64.00	High
11/1/2019	Royal Bank of Canada	Set Target	Buy	$79.00	N/A
10/31/2019	Needham & Company LLC	Reiterated Rating	Buy	$71.00	High
10/28/2019	Piper Sandler Companies	Lower Target	Overweight	$80.00 ➝ $70.00	High
10/1/2019	Royal Bank of Canada	Lower Target	Outperform	$82.00	High
9/30/2019	Cowen	Reiterated Rating	Buy		High
9/24/2019	Piper Sandler Companies	Set Target	Buy	$80.00	Medium
9/23/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$55.00	Low
9/12/2019	BMO Capital Markets	Initiated Coverage	Outperform	$45.00	Low
8/2/2019	Royal Bank of Canada	Set Target	Buy	$89.00	Medium
5/31/2019	Cowen	Reiterated Rating	Buy		High
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$55.00	Medium
5/16/2019	Royal Bank of Canada	Boost Target		$90.00	High
5/16/2019	Cowen	Reiterated Rating	Buy		High
5/3/2019	Piper Sandler Companies	Lower Target	Overweight	$100.00 ➝ $85.00	High

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

6 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/28/2023

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/28/2023

4 very positive mentions
7 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/27/2023

1 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/27/2023

11 very positive mentions
13 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

1/26/2024

16 very positive mentions
14 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

2/25/2024

2 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/26/2024

4 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $31.67

$31.32

$32.26

50 Day Range

MA: $29.80

$25.90

$34.81

52 Week Range

Now: $31.67

$19.80

$35.50

Volume

643,302 shs

Average Volume

809,281 shs

Market Capitalization

$1.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Agios Pharmaceuticals?: The following Wall Street research analysts have issued reports on Agios Pharmaceuticals in the last twelve months: Cantor Fitzgerald, JPMorgan Chase & Co., Royal Bank of Canada, StockNews.com, SVB Securities, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for AGIO.
What is the current price target for Agios Pharmaceuticals?: 4 Wall Street analysts have set twelve-month price targets for Agios Pharmaceuticals in the last year. Their average twelve-month price target is $33.50, suggesting a possible upside of 5.8%. Royal Bank of Canada has the highest price target set, predicting AGIO will reach $42.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $28.00 for Agios Pharmaceuticals in the next year.
View the latest price targets for AGIO.
What is the current consensus analyst rating for Agios Pharmaceuticals?: Agios Pharmaceuticals currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AGIO.
What other companies compete with Agios Pharmaceuticals?: Other companies that are similar to Agios Pharmaceuticals include Syndax Pharmaceuticals, Schrödinger, Catalyst Pharmaceuticals, Structure Therapeutics and Geron. Learn More about companies similar to Agios Pharmaceuticals.
How do I contact Agios Pharmaceuticals' investor relations team?: Agios Pharmaceuticals' physical mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is (617) 649-8600 and its investor relations email address is [email protected]. The official website for Agios Pharmaceuticals is www.agios.com. Learn More about contacing Agios Pharmaceuticals investor relations.

Agios Pharmaceuticals - AGIO Stock Price Target and Predictions

Analyst Price Target for AGIO

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.80 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Agios Pharmaceuticals?

What is the current price target for Agios Pharmaceuticals?

What is the current consensus analyst rating for Agios Pharmaceuticals?

What other companies compete with Agios Pharmaceuticals?

How do I contact Agios Pharmaceuticals' investor relations team?